StockTipsArenaBeta

BUY Morepen Laboratories Limited — Swati Hotkar, Nirmal Bang Securities

BUYMorepen Laboratories Limited
Morepen Laboratories share price target & all analyst calls

bySwati Hotkar, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))6 Oct 2026via NDTV Profit (Live)

Entry₹141.72Inferred
Target₹150
Total upside +5.84%
Stop loss₹135-4.74% risk
CMP₹143.96Just now
Active+1.58%+4.20%upside left 13d left
Follow Swati Hotkar for new calls(15% target hit, 47 closed calls)Get alertsWatch MOREPENLAB for new buy/sell callsGet alertsSee 2 other Swing calls on MOREPENLABSee 155 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 6 Oct, 4:20 pm IST
5 supporting1 opposing
Supports the BUY call (5)

Morepen Laboratories के शेयर में 19.5% उछाल, तेज़ी से बढ़ रहे CDMO क्षेत्र में प्रवेश के लिए, ₹825 करोड़ का वैश्विक प्रोजेक्ट मिलने के बाद।

NewsGoogle News·6 Oct · today

(opens in new tab)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·1 Oct · 5d ago

Morepen Laboratories promotes Sanjay Suri to MD

NewsGoogle News·30 Sept · 6d ago

(opens in new tab)

Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA, marking a significant step in expanding its integrated CDMO capabilities.

NSE · Press Release·28 Sept · 1w ago

(opens in new tab)

Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets, marking an expansion into integrated finished dosage development.

BSE · Company Update·28 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·6 Oct · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Morepen Laboratories

All analyst calls on Morepen Laboratories

More from Swati Hotkar, Nirmal Bang Securities

Every call and its outcome